Stevie C Britch1, Jenny L Wiley2, Zhihao Yu3, Brian H Clowers3, Rebecca M Craft4. 1. Department of Psychology, Washington State University, Pullman, WA, 99164-4820, USA. 2. RTI International, Research Triangle Park, NC, 27709-2194, USA. 3. Department of Chemistry, Washington State University, Pullman, WA, 99164-4630, USA. 4. Department of Psychology, Washington State University, Pullman, WA, 99164-4820, USA. Electronic address: craft@wsu.edu.
Abstract
BACKGROUND: Previous studies suggest that cannabidiol (CBD) may potentiate or antagonize Δ9-tetrahydrocannabinol's (THC) effects. The current study examined sex differences in CBD modulation of THC-induced antinociception, hypolocomotion, and metabolism. METHODS: In Experiment 1, CBD (0, 10 or 30mg/kg) was administered 15min before THC (0, 1.8, 3.2, 5.6 or 10mg/kg), and rats were tested for antinociception and locomotion 15-360min post-THC injection. In Experiments 2 and 3, CBD (30mg/kg) was administered 13h or 15min before THC (1.8mg/kg); rats were tested for antinociception and locomotion 30-480min post-THC injection (Experiment 2), or serum samples were taken 30-360min post-THC injection to examine CBD modulation of THC metabolism (Experiment 3). RESULTS: In Experiment 1, CBD alone produced no antinociceptive effects, while enhancing THC-induced paw pressure but not tail withdrawal antinociception 4-6h post-THC injection. CBD alone increased locomotor activity at 6h post-injection, but enhanced THC-induced hypolocomotion 4-6h post-THC injection, at lower THC doses. There were no sex differences in CBD-THC interactions. In Experiments 2 and 3, CBD did not significantly enhance THC's effects when CBD was administered 13h or 15min before THC; however, CBD inhibited THC metabolism, and this effect was greater in females than males. CONCLUSIONS: These results suggest that CBD may enhance THC's antinociceptive and hypolocomotive effects, primarily prolonging THC's duration of action; however, these effects were small and inconsistent across experiments. CBD inhibition of THC metabolism as well other mechanisms likely contribute to CBD-THC interactions on behavior.
BACKGROUND: Previous studies suggest that cannabidiol (CBD) may potentiate or antagonize Δ9-tetrahydrocannabinol's (THC) effects. The current study examined sex differences in CBD modulation of THC-induced antinociception, hypolocomotion, and metabolism. METHODS: In Experiment 1, CBD (0, 10 or 30mg/kg) was administered 15min before THC (0, 1.8, 3.2, 5.6 or 10mg/kg), and rats were tested for antinociception and locomotion 15-360min post-THC injection. In Experiments 2 and 3, CBD (30mg/kg) was administered 13h or 15min before THC (1.8mg/kg); rats were tested for antinociception and locomotion 30-480min post-THC injection (Experiment 2), or serum samples were taken 30-360min post-THC injection to examine CBD modulation of THC metabolism (Experiment 3). RESULTS: In Experiment 1, CBD alone produced no antinociceptive effects, while enhancing THC-induced paw pressure but not tail withdrawal antinociception 4-6h post-THC injection. CBD alone increased locomotor activity at 6h post-injection, but enhanced THC-induced hypolocomotion4-6h post-THC injection, at lower THC doses. There were no sex differences in CBD-THC interactions. In Experiments 2 and 3, CBD did not significantly enhance THC's effects when CBD was administered 13h or 15min before THC; however, CBD inhibited THC metabolism, and this effect was greater in females than males. CONCLUSIONS: These results suggest that CBD may enhance THC's antinociceptive and hypolocomotive effects, primarily prolonging THC's duration of action; however, these effects were small and inconsistent across experiments. CBD inhibition of THC metabolism as well other mechanisms likely contribute to CBD-THC interactions on behavior.
Authors: S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin Journal: Psychopharmacology (Berl) Date: 2006-03-30 Impact factor: 4.530
Authors: Jahan P Marcu; Rigel T Christian; Darryl Lau; Anne J Zielinski; Maxx P Horowitz; Jasmine Lee; Arash Pakdel; Juanita Allison; Chandani Limbad; Dan H Moore; Garret L Yount; Pierre-Yves Desprez; Sean D McAllister Journal: Mol Cancer Ther Date: 2010-01-06 Impact factor: 6.261
Authors: Eva M Romero; Beatriz Fernández; Onintza Sagredo; Nuria Gomez; Leyre Urigüen; Carmen Guaza; Rosario De Miguel; Jose Antonio Ramos; M Paz Viveros Journal: Brain Res Dev Brain Res Date: 2002-06-30
Authors: Nicholas Z Greene; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft Journal: Psychopharmacology (Berl) Date: 2018-09-20 Impact factor: 4.530
Authors: Henry L Blanton; Jennifer Brelsfoard; Nathan DeTurk; Kevin Pruitt; Madhusudhanan Narasimhan; Daniel J Morgan; Josée Guindon Journal: Drugs Date: 2019-06 Impact factor: 9.546
Authors: Jacques D Nguyen; Yanabel Grant; Kevin M Creehan; Candy S Hwang; Sophia A Vandewater; Kim D Janda; Maury Cole; Michael A Taffe Journal: Neuropharmacology Date: 2019-04-11 Impact factor: 5.250
Authors: Stevie C Britch; Alan G Goodman; Jenny L Wiley; Abby M Pondelick; Rebecca M Craft Journal: J Pharmacol Exp Ther Date: 2020-03-16 Impact factor: 4.030
Authors: Alyssa M Myers; Patrick B Siegele; Jeffrey D Foss; Ronald F Tuma; Sara Jane Ward Journal: Br J Pharmacol Date: 2018-03-01 Impact factor: 8.739